Search
Roivant Sciences Ltd
ROIVAdd to Watchlist
33.910USD
-0.610-1.77%
Close 07-31 16:00（ET）Quotes delayed by 15 min
24.43BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Roivant Sciences Ltd is 8.77, ranking 6 out of 155 in the Pharmaceuticals industry. The average price target is 24.00, with a high of 29.00 and a low of 20.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
37.528
Target Price
+14.17%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Roivant Sciences Ltd
ROIV
12
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Roivant Sciences Ltd's expected revenue for the next quarter?
Roivant Sciences Ltd's expected revenue is 2.06M.
What is Roivant Sciences Ltd's price target?
Analysts forecast that Roivant Sciences Ltd's price target is USD 24.00, with the highest forecast at USD 29.00 and the lowest forecast at USD 20.00.
How have Roivant Sciences LtdROIV's recent earnings per share performed?
The market expectation was USD 0.42, while Roivant Sciences LtdROIV's earnings per share (EPS) for the previous quarter was USD -0.38. EPS for the next quarter is expected at USD -0.32.
What is the analyst rating for Roivant Sciences Ltd?
Based on the ratings of Roivant Sciences Ltd's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.